Campath (alemtuzumab) / Bayer, Sanofi 
Welcome,         Profile    Billing    Logout  

7 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Campath (alemtuzumab) / Sanofi
NCT01361711: Alemtuzumab-Ofatumumab in Previously Untreated Symptomatic Chronic Lymphocytic Leukemia

Active, not recruiting
2
53
Europe, US
alemtuzumab, anti-CD52 monoclonal antibody, Campath-1H, MoAb CD52, Monoclonal Antibody Campath-1H, Monoclonal Antibody CD52, ofatumumab, Arzerra, HuMax-CD20, biopsy, biopsies
Northwestern University, GlaxoSmithKline, National Comprehensive Cancer Network
Stage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocytic Leukemia, Stage III Chronic Lymphocytic Leukemia, Stage IV Chronic Lymphocytic Leukemia
08/15
05/27
NCT04312841: Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With Alemtuzumab

Active, not recruiting
2
6
US
Letermovir, 2-((4S)-8-Fluoro-2-(4-(3-methoxyphenyl)piperazin-1-yl)-3-(2-methoxy-5-(trifluoromethyl)phenyl)-4H-quinazolin-4-yl)acetic Acid, AIC246, MK-8228, Prevymis
Ohio State University Comprehensive Cancer Center, Merck Sharp & Dohme LLC
B-Cell Prolymphocytic Leukemia, Chronic Lymphocytic Leukemia, Peripheral T-Cell Lymphoma, Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Sezary Syndrome, T-Cell Prolymphocytic Leukemia
04/24
12/24
SUN-RAY, NCT06358638: Sickle Cell Disease Transplant Using a Nonmyeloablative Approach for Patients With Anti-donor Red Cell AntibodY

Recruiting
2
12
US
Daratumumab, Darzalex, Alemtuzumab, Campath-1H, Sirolimus, Rapamune, Total Body Irradiation, TBI
Children's National Research Institute, Alberta Children's Hospital, The Hospital for Sick Children, Levine Children's Hospital, Ann & Robert H Lurie Children's Hospital of Chicago, Nationwide Children's Hospital, Children's Hospital at Montefiore, Doris Duke Charitable Foundation, Janssen Pharmaceuticals
Sickle Cell Disease
09/44
09/54
BALLI-01, NCT04150497: Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia

Recruiting
1/2
40
Europe, US
UCART22, CLLS52, Alemtuzumab
Cellectis S.A.
B-cell Acute Lymphoblastic Leukemia
12/23
01/26
NatHaLi-01, NCT05607420: Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma

Recruiting
1/2
80
Europe, US
UCART20x22, CLLS52, Alemtuzumab
Cellectis S.A.
B-cell Non-Hodgkin Lymphoma (B-NHL)
11/27
11/27
aGVHD，hAESCs, NCT06164288: Safety and Efficacy Study of hAESCs Therapy for aGVHD

Not yet recruiting
1
18
NA
Human Amniotic Epithelial Stem Cell Injection
Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China
GVHD,Acute
12/24
06/25
TEACH, NCT03504241: Tolerance by Engaging Antigen During Cellular Homeostasis

Active, not recruiting
1
8
US
Donor-derived Mesenchymal Stromal Cells, Donor-derived MSCs, human bone marrow derived MSCs, hBM-MSC, EPIC-MSC-ITN2015-IVF-0X, alemtuzumab, Campath®, Lemtrada®, belatacept, Nulojix®, LEA29Y, sirolimus, Rapamune®, mycophenolate mofetil, CellCept®, mycophenolate acid, Myfortic®, prednisone, corticosteroid
National Institute of Allergy and Infectious Diseases (NIAID), Immune Tolerance Network (ITN), PPD, Rho Federal Systems Division, Inc.
Kidney Transplantation, Renal Transplantation, Renal Transplant Recipient
12/27
12/29

Download Options